Additionally, the patients were required to have a documented genotype and be ARV-na€ ıve. A medical chart review was conducted to assess demographic information, disease burden, and risk factors for acquiring the virus.
Introduction
Widespread use of antiretrovirals (ARVs) for the treatment of HIV-1 infection in developed countries has been accompanied by an increase in transmitted drug resistance (TDR) in ARV-na€ ıve patients in the USA [1] . Resistant HIV may be acquired from failed antiretroviral therapy (ART) or through TDR [2] . The World Health Organization (WHO) defines TDR as resistance in an ART-na€ ıve individual transmitted directly, or through intermediates, from a person with acquired drug resistance from failed ART [3] . TDR prevalence rates vary with ARV drug class, geographical location, and risk factors for exposure to HIV [4] . Initial ART is more likely to fail in patients who are infected with drug-resistant virus [1, 5] . In the USA, 1.2 million people are infected with HIV and 37% of this community are prescribed ART, of those with HIV 30% being virologically suppressed [6] . However, of those persons engaged in HIV care, 92% were found to have been prescribed ART and 76% to have achieved viral suppression [7] . Reasons for inadequate immunological response include poor or intermittent medication adherence, delays in testing or initiating treatment, poor long-term retention in HIV care, or other unexplained biological reasons [8, 9] . The Department of Health and Human Services (DHHS) Panel on ARV Guidelines for Adults and Adolescents recommends baseline drug resistance testing for all persons infected with HIV prior to initiating therapy [8, 10] .
The prevalence of TDR in the USA is reported to be between 11.3% and 24.5% of HIV-positive persons [1, 4, 9, [11] [12] [13] [14] [15] [16] . From 2008 to 2010, the overall prevalence of TDR in Europe was 8.3% and was not found to change over time [17] . These baseline mutations were most predictive of resistance to efavirenz-or rilpivirine-containing regimens. Other regions of the world with less established use of ART, such as Africa and Asia, report much lower rates of TDR (< 1-8.7%) [1, [17] [18] [19] [20] . The drug class with the highest baseline resistance identified is NRTIs, with reported rates between 1% and 15.8% [11, 13, 14, 16, 17, [21] [22] [23] [24] . Similarly, reported TDR rates range from 1.4 to 10.6% for NNRTIs and 0.7 to 4.5% for PIs [11, 12, 14, 16, 17, [21] [22] [23] [24] . Baseline TDR rates for integrase strand transfer inhibitors (INSTIs) are largely unknown, as resistance for this class is not routinely determined at baseline unless there is concern about transmitted INSTI resistance and the provider is considering an INSTI as part of the ART [8] . Current evidence reveals no increase in mutations conferring resistance to INSTIs in countries such as Switzerland and Austria [25, 26] . However, recent data revealed a statistically significant increase in prevalence of resistance to INSTIs in British Columbia from 2009 to 2015 [27] .
Another concern is multi-drug resistance (MDR) with double and triple class mutations. The frequency has increased from 1.1 to 6.2% in the last decade [5] . Approximately 5.4-10.3% of individuals with recently diagnosed HIV infection had dual class resistance and 0.9-3.8% had triple drug class resistance [16, 28] . Of men who have sex with men (MSM) who recently acquired HIV-1 infection, 3.6% had MDR and 1.5% had resistance to at least three ARV drug classes [29] . Reduced susceptibility to one or more drugs is significantly higher for white populations compared with black or Hispanic populations [21] . The Centers for Disease Control and Prevention (CDC) reported that, among persons newly diagnosed with HIV infection from 1997 to 2001, TDR prevalence was 5.4% in non-Hispanic black individuals and 13% among non-Hispanic white individuals [14] .
The prevalence of TDR in MSM individuals, women, and heterosexual men was reported to be 8.7-28%, 6.1%, and 4.7%, respectively [14, 30, 31] . Individuals who identified themselves to be bisexual had TDR rates of 27.8% [23] . For recently infected persons whose sexual partners reported taking ARV medications, TDR was reported to be 15.2% [14] .
Resistance to ART has many implications for managing the treatment of HIV infection, such as the higher probability of virological failure (VF) with first-line ARV regimens in ARV-na€ ıve patients [5, 15] . In a recent study evaluating the response to therapy in ART-na€ ıve patients with NNRTIassociated TDR, VF, defined as not reaching an undetectable viral load within 24 weeks, occurred primarily in patients receiving two NRTIs plus an NNRTI (25%) compared with PI-based therapy (15%) or INSTI-based therapy (2%), and patients receiving two NRTIs plus a PI (15%), INSTI (2%), or NNRTI (25%) [32] . Although the prevalence of TDR within the general population of the USA and other countries has been the focus of many investigations, rates of TDR in the correctional population remain largely unknown.
In 2010, 1.61 million people were incarcerated in the federal and state prison system [33] . Of these, 20 093 prisoners had HIV infection, with 91% being male. Recent statistics show that the incarcerated population in the USA is constituted of 58.9% white, 37.6% black, and 34.0% Hispanic individuals [34] . Among the incarcerated population, black men are five times more likely than white men and twice as likely as Hispanic men to be diagnosed with HIV infection [33] . HIV prevalence in state prison inmates may be more than five times higher than in the general population but transmission within the incarcerated population is not well documented [35] . Inmates often engage in high-risk behaviour such as injecting drug use, unprotected sex, and needle sharing [33] . Some prison administrators do not provide services such as HIV testing or prevention in correctional facilities because of high costs [33] . Despite TDR being a topic of great interest, there are still limited data, especially on resistant virus in the correctional population. The objective of this study was to evaluate the prevalence and type of TDR in HIV-1-positive ARV-na€ ıve patients incarcerated in the Illinois Department of Corrections (IDOC).
Methods
This study was a retrospective cohort study of HIV-1-positive patients incarcerated in the IDOC and receiving medical care through a telemedicine service provided by HIVtrained physicians, clinical pharmacists, and a case manager at the University of Illinois at Chicago (UIC) Hospital between the dates of 10 July 2010 and 29 April 2016. This institutional review board (IRB)-approved study included ARV-na€ ıve, HIV-1-positive adult prisoners with a baseline genotype determined prior to initiation of ART. An electronic medical chart review was conducted to assess demographic information as well as CD4 count, CD4 percentage, viral load, risk factor, time since HIV diagnosis, baseline NRTI mutation(s), NNRTI mutation(s), and PI mutation(s), past medical history (sexually transmitted infections, hepatitis status and psychiatric illness), and social history (alcohol use and illicit drug use).
Study endpoints
The primary endpoints of the study were the percentage of individuals with baseline TDR and the classes of TDR represented. Resistance mutations were considered clinically significant if the drug resistance interpretation showed some level of resistance to an ARV according to the Stanford HIV database [36] . The secondary endpoint was the type of ARV mutation(s) present at baseline.
Statistical analysis
Descriptive statistics were utilized for demographic data. For categorical data, the chi-square test was utilized. The independent sample t-test was used for continuous variables.
Results

Patient characteristics
The inclusion criteria were met for 105 patients with baseline characteristics as described in Table 1 . The mean age was 34 years (range 19-60 years). The most common race was black (82%), followed by white (9%) and Hispanic (8%). The most common patient risk factor or group reported was heterosexual (70.5%), followed by MSM (14%), blood-related (11%), and bisexual (10%). Seven per cent of patients self-reported more than one risk factor or group. The median baseline CD4 cell count was 374 cells/lL (range 2À1679 cells/lL) and the median baseline HIV RNA value was 19 964 HIV-1 RNA copies/mL (range 236À4 241 178 copies/mL). Approximately 79% of patients had an HIV RNA value of < 100 000 copies/mL. Demographic data for patients with clinically significant mutations were not significantly different from those for patients without TDR.
Prevalence of clinically significant antiretroviral resistance mutations
The prevalence of clinically significant mutations by class is described in Table 2 . A total of 24 patients (23%) had a clinically significant mutation associated with resistance to any drug class. The prevalence of mutations conferring clinically significant resistance was 19% for NNRTIs, 18% for NRTIs, and 4% for PIs. Five per cent of patients had dual-class TDR to both [36] . Specific resistance mutations observed are described in Table 2 . The most frequently observed mutations in this cohort were those associated with resistance to the NRTI class, specifically T215 and K103, which were each observed in 10 patients in this sample. Additionally, variants at the M41 and V106 positions were also frequently seen, conferring resistance to the NRTI and NNRTI classes, respectively.
Patient factors associated with prevalence of drug resistance
There was no significant increase in the prevalence of clinically relevant drug resistance mutations based on race, age, baseline burden of disease, or risk factor for acquisition of the virus (Table 1) . Interestingly, all three of the patients with tattoos as a risk factor had clinically significant mutations present, specifically those associated with resistance to NNRTIs. None of the other risk factors were associated with a significant difference in the prevalence of ARV resistance mutations. Table 3 describes specific resistance mutations by class according to patient risk factors. About 24% of patients who self-identified as heterosexual had clinically significant resistance and 20% of patients who self-identified as MSM had clinically significant mutations. Patients with clinically significant resistance did not have a significantly different baseline CD4 cell count; however, a statistically significant difference in baseline HIV RNA level was found between patients with and without clinically significant mutations (P = 0.02). Patients with clinically significant mutations were more likely to have a lower baseline HIV RNA value of < 100 000 copies/mL than patients without significant resistance (Table 1) .
Discussion
To our knowledge, this study is one of the first to describe the prevalence of TDR in a correctional setting. The incidence and type of TDR in the incarcerated population were largely unknown prior to conducting this study. The prevalence of TDR that we found in the incarcerated population is consistent with the higher end of the prevalence range of TDR in the general population previously reported in the USA (11.3À24.5%) [1, 4, [10] [11] [12] [13] [14] [15] . The most frequently observed mutation was an NNRTIassociated mutation, which is consistent with previous published studies [15] . It is known that the NNRTI class has a lower genetic barrier to resistance compared with PIs and INSTIs. A higher number of mutations is required to confer resistance to PIs and INSTIs than to NRTIs and NNRTIs, which have the lowest genetic barrier to resistance of all of the ARV classes [37] . Agents that are more robust, such as the PIs and INSTIs, constitute the preferred regimens in the USA [8] . NNRTIs are preferred in other parts of the world and are still used as alternative agents for various reasons such as affordability, side effects, and specific genetic mutations. We found that the prevalence of TDR to NRTIs, NNRTIs and PIs was 18%, 19% and 4%, respectively. These rates were also consistently higher than previously reported [11, 12, 14, 16, [21] [22] [23] [24] . However, the frequency of dual class resistance was consistent with rates previously reported previously in the general population (5.4-10.3%) [5, 16, 28] . The baseline demographics of the subjects in our study were relatively consistent with the results of previous studies on the general population affected by the HIV epidemic, with 82% of the study population identifying as black men [14] . There was no significant increase in the prevalence of clinically relevant drug resistance mutations based on race or age. However, a higher percentage of white individuals in our study had clinically significant mutations (33%) than black individuals (22%) or Hispanics (25%), similar to what was observed in previous studies [14, 21] . Higher rates of TDR are reported in communities or groups who engage in riskier behaviours [14, 23, 28, 29] . It is possible that the higher prevalence of TDR in our study population was attributable to the high prevalence of risk factors for transmission within the incarcerated population, including homosexual or bisexual orientation, injecting drug use, blood transfusions, and unprofessional tattoos obtained in the correctional setting. The prevalence of TDR in individuals who identified themselves to be MSM and bisexual in the general population (8.7-28% and 27.8%, respectively) was higher than in the heterosexual population and was similar to the results found in our study [14, 23, 30, 31] .
Although we do not know when each individual patient was infected with the virus, the genotypic testing is probably accurate because TDR mutations remain longer than archived mutations secondary to selective drug pressure [38] . The median time for resistance mutations to become undetectable ranged from 4.1 years to the patient's lifetime. The persistence of TDR in treatment-na€ ıve patients supports baseline genotype resistance testing for all patients prior to starting treatment, especially with the high rates of resistance found.
In accordance with current recommendations, our HIV telemedicine clinic only performed genotypic resistance testing on the reverse transcriptase and protease genes [8] . Standard testing for resistance to INSTIs was not performed in this study. However, several reports of TDR to INSTIs have surfaced in recent studies (0.1À2.3%), which may warrant future research in ARV-na€ ıve patients [25, 39, 40] . It is likely that baseline integrase resistance testing will be recommended in the future as more cases of transmitted integrase resistance are reported.
Although only antiretroviral-na€ ıve prisoners with genotype resistance testing available were included in the study, this strategy did not lead to a selection bias as this is standard of care for all na€ ıve patients regardless of clinic setting. Genotype testing was not routinely performed unless a patient had a loss of virological suppression or there was a concern about the presence of resistance. Therefore, all antiretroviral-na€ ıve patients received genotype testing to determine appropriate management.
A limitation of this study is that the study design was observational and retrospective. Another limitation of the study was that risk factor information collected was selfreported. It is possible that the prevalence of various risk factors were understated in our study population because of the stigma of identifying as MSM or bisexual in prison. If incarcerated individuals were not truthful when asked about these characteristics, this would imply that reports of transmission through heterosexual intercourse would be overestimated and that transmission by other routes would be underestimated in our analysis. There is also an issue of privacy in prison that potentially impacted patients' self-reporting. If patients believed that someone could overhear conversations with the medical staff or that the telemedicine appointment was not encrypted or secure, it may have influenced them to reduce or not report certain risk factors that may be associated with overestimation of the risk factor leading to HIV. There is evidence that patients are not truthful about various risk factors for acquiring HIV, including anal intercourse and injecting drug use [41, 42] . For example, in a study about soldiers lying to military physicians 3 (20) 0 (0) 1 (7) 1 (7) 0 (0) 1 (7) 12 ( about their risk factors, 75% of HIV-positive soldiers selfreported that they had acquired the virus through heterosexual intercourse; however, 12 of the 15 patients later admitted to acquiring the virus through homosexual intercourse or injecting drug use [42] . Finally, a larger sample size may have revealed more differences between the subjects with and without clinically significant mutations, such as race or risk factors. Despite these limitations, this is the first description of the prevalence of TDR in the correctional setting, to our knowledge. The WHO developed a list of drug resistance mutations for epidemiological estimates of transmitted resistance in 2007 [3] . The WHO list is comparable to the Stanford HIV database susceptibilities used in this study, with the exception of a few differences in rotations: the Stanford HIV database included V108I/V, E138G, and Y188L (NNRTI mutations) as well as K20I and Q58E (PI mutations) as clinically significant at the time of the study [3, 36] . These five mutations found to be clinically significant by the Stanford HIV database (Table 2) were not included in the list published by the WHO. There are a few possible explanations for these discrepancies. The mutations could have been found to be more relevant after the WHO list was published, they could differ in the level of resistance they confer in the USA compared with other parts of the world, or the discrepancies could be a result of the difference in first-line ART options in the DHHS guidelines as compared with the WHO's recommendations. According to the DHHS guidelines, the recommended first-line regimens in the USA are integrase-based or boosted PI regimen-based regimens with an NRTI backbone [8] . In contrast, tenofovir/emtricitabine/efavirenz is the preferred option for initiating ART according to the WHO, with other NRTI-or NNRTIcontaining regimens listed as alternatives. Additionally, the WHO does not currently recommend routine genotype resistance testing in ART-na€ ıve patients because of barriers including the cost and complexity of routine testing [43] . Using efavirenz resistance to show the importance of testing for resistance to all of these agents, we calculated that, out of the 24 patients with clinically significant mutations in our study, 14 patients (58%) had mutations conferring significant resistance to efavirenz. In other words, 13.3% of the entire sample population had some sort of resistance to efavirenz, supporting the need for baseline resistance testing.
The incarcerated population remains largely unstudied; however, reports state that the prevalence of HIV infection in the incarcerated population is about four times higher than in the general population (1.5 vs. 0.4%, respectively) [33, 44] . Therefore, prisoners are a high-prevalence subpopulation that represents a captive audience for engagement in the management of their HIV infection [45] . This study involved prisoners from 27 correctional facilities in Illinois, USA. The prisoner populations vary in geographical location from inner city to rural, and range from transitional security, minimum security, medium security, maximum security, to multi-security facilities [46] . In 2013, the breakdown of criminal offences committed by those incarcerated by the IDOC was similar to those in other states, with 45% committed for a violent offense, 20% for a drug or property crime, and 13% for a sex crime [47] . Interestingly, the crime rate in Illinois was about 16% lower than the national average rate at about 2737 crimes per 100 000 people in 2015 [48] . As there have been no other data published regarding the TDR prevalence in other states' Departments of Correction, we cannot conclude with certainty that the prevalence found in the IDOC population can be extrapolated to other prisons. However, the prevalence of known HIV infection cases in inmates was comparable in Illinois (1.0%) and nationally (1.5%). Therefore, our results are likely to be generalizable to other prisons in the USA [49] . In our study, we observed a higher rate of TDR in these individuals than the general population. This increase in the prevalence of TDR is possibly attributable to the increase in engagement in high-risk behaviours, such as injecting drug use or unprotected sex, that is seen in the incarcerated population [33] . An important implication of the results found in this study is the increase of the prevalence of TDR that may be seen as incarcerated individuals are released from prison, return to the community, and possibly spread resistance to the nonincarcerated population. It is vital for prisons to provide improved strategies for managing and identifying HIV infection, despite barriers such as funding or access to HIV experts [45] . It has been reported that specialty HIV services, such as telemedicine, within the prison system have resulted in improved virological suppression, immunological function, and patient compliance.
Conclusions
A high prevalence of TDR was identified in the HIV-positive, ARV-na€ ıve incarcerated population. Transmitted HIV drug resistance was detected in approximately 23% of the patients initiating ART in the IDOC setting [45] . The prevalence of mutations conferring clinically significant resistance was 19% for NNRTIs, 18% for NRTIs, and 4% for PIs. The results of this study indicate an increased prevalence of TDR in a largely unstudied incarcerated population and add to the growing body of evidence demonstrating the need for increased monitoring of resistance in HIV-infected patients world-wide. In addition,
